Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.07
NYSE:STJ's Cash to Debt is ranked lower than
93% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NYSE:STJ: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:STJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.34 Max: No Debt
Current: 0.07
Equity to Asset 0.36
NYSE:STJ's Equity to Asset is ranked lower than
81% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:STJ: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:STJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.55 Max: 0.83
Current: 0.36
0.31
0.83
Interest Coverage 5.81
NYSE:STJ's Interest Coverage is ranked lower than
84% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. NYSE:STJ: 5.81 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:STJ' s Interest Coverage Range Over the Past 10 Years
Min: 5.81  Med: 15.5 Max: 24.41
Current: 5.81
5.81
24.41
F-Score: 4
Z-Score: 3.02
M-Score: -2.34
WACC vs ROIC
8.51%
9.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.51
NYSE:STJ's Operating margin (%) is ranked higher than
82% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NYSE:STJ: 15.51 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:STJ' s Operating margin (%) Range Over the Past 10 Years
Min: 15.01  Med: 20.23 Max: 24.73
Current: 15.51
15.01
24.73
Net-margin (%) 11.05
NYSE:STJ's Net-margin (%) is ranked higher than
79% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NYSE:STJ: 11.05 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:STJ' s Net-margin (%) Range Over the Past 10 Years
Min: 8.09  Med: 15.34 Max: 17.82
Current: 11.05
8.09
17.82
ROE (%) 15.74
NYSE:STJ's ROE (%) is ranked higher than
82% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. NYSE:STJ: 15.74 )
Ranked among companies with meaningful ROE (%) only.
NYSE:STJ' s ROE (%) Range Over the Past 10 Years
Min: 11.45  Med: 18.85 Max: 23.77
Current: 15.74
11.45
23.77
ROA (%) 5.33
NYSE:STJ's ROA (%) is ranked higher than
69% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NYSE:STJ: 5.33 )
Ranked among companies with meaningful ROA (%) only.
NYSE:STJ' s ROA (%) Range Over the Past 10 Years
Min: 5.33  Med: 9.57 Max: 12.8
Current: 5.33
5.33
12.8
ROC (Joel Greenblatt) (%) 33.13
NYSE:STJ's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NYSE:STJ: 33.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:STJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 33.13  Med: 41.7 Max: 55.1
Current: 33.13
33.13
55.1
Revenue Growth (3Y)(%) 3.50
NYSE:STJ's Revenue Growth (3Y)(%) is ranked lower than
52% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NYSE:STJ: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:STJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.7  Med: 11.2 Max: 21
Current: 3.5
-6.7
21
EBITDA Growth (3Y)(%) 3.30
NYSE:STJ's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. NYSE:STJ: 3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:STJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.6  Med: 14.6 Max: 22.3
Current: 3.3
-4.6
22.3
EPS Growth (3Y)(%) 8.70
NYSE:STJ's EPS Growth (3Y)(%) is ranked higher than
58% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NYSE:STJ: 8.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:STJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.1  Med: 13.1 Max: 117.9
Current: 8.7
-36.1
117.9
» NYSE:STJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

STJ Guru Trades in Q4 2015

Jeff Auxier 22,019 sh (New)
Joel Greenblatt 32,724 sh (+231.89%)
Jim Simons 806,113 sh (+203.26%)
Ray Dalio 77,167 sh (+39.75%)
Keeley Asset Management Corp 9,315 sh (+18.89%)
Mairs and Power 2,258,163 sh (+11.42%)
John Rogers 1,333,643 sh (+0.73%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
Mario Gabelli 8,400 sh (unchged)
John Hussman Sold Out
David Dreman Sold Out
Barrow, Hanley, Mewhinney & Strauss 2,978,770 sh (-0.38%)
Ken Fisher 255,140 sh (-2.17%)
Jeremy Grantham 792,255 sh (-8.27%)
Paul Tudor Jones 5,529 sh (-12.97%)
RS Investment Management 48,940 sh (-30.97%)
» More
Q1 2016

STJ Guru Trades in Q1 2016

David Dreman 17,529 sh (New)
Leucadia National 4,700 sh (New)
Steven Cohen 3,200 sh (New)
Keeley Asset Management Corp 23,950 sh (+157.11%)
Jim Simons 1,920,213 sh (+138.21%)
Ray Dalio 114,830 sh (+48.81%)
Jeff Auxier 31,972 sh (+45.20%)
John Rogers 1,850,653 sh (+38.77%)
Mairs and Power 2,936,518 sh (+30.04%)
Ken Fisher 258,311 sh (+1.24%)
Barrow, Hanley, Mewhinney & Strauss 2,983,270 sh (+0.15%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
Mario Gabelli 8,400 sh (unchged)
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Jeremy Grantham 757,155 sh (-4.43%)
» More
Q2 2016

STJ Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 32,887 sh (New)
Richard Perry 265,000 sh (New)
Joel Greenblatt 46,348 sh (New)
Paul Tudor Jones 331,990 sh (New)
George Soros 38,860 sh (New)
John Paulson 45,500 sh (New)
Mario Gabelli 74,400 sh (+785.71%)
Leucadia National 20,000 sh (+325.53%)
Jeremy Grantham 1,372,968 sh (+81.33%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
Jeff Auxier 31,973 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Ray Dalio Sold Out
Steven Cohen Sold Out
Mairs and Power 2,912,404 sh (-0.82%)
David Dreman 16,913 sh (-3.51%)
Ken Fisher 237,317 sh (-8.13%)
John Rogers 959,830 sh (-48.14%)
Keeley Asset Management Corp 12,220 sh (-48.98%)
Jim Simons 150,000 sh (-92.19%)
» More
Q3 2016

STJ Guru Trades in Q3 2016

First Eagle Investment 545,389 sh (New)
Daniel Loeb 2,600,000 sh (New)
Eric Mindich 1,467,100 sh (New)
Paul Singer 250,249 sh (New)
Leucadia National 53,200 sh (+166.00%)
John Paulson 94,500 sh (+107.69%)
Manning & Napier Advisors, Inc 33,297 sh (+1.25%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
Paul Tudor Jones 400,000 sh (unchged)
Ken Fisher Sold Out
Richard Perry Sold Out
Keeley Asset Management Corp Sold Out
Jim Simons Sold Out
George Soros Sold Out
Mairs and Power 2,892,464 sh (-0.68%)
Jeff Auxier 31,374 sh (-1.87%)
Jeremy Grantham 1,244,444 sh (-9.36%)
Mario Gabelli 66,900 sh (-10.08%)
Paul Tudor Jones 157,700 sh (-52.50%)
Joel Greenblatt 6,069 sh (-86.91%)
John Rogers 94,498 sh (-90.15%)
David Dreman 51 sh (-99.70%)
» More
» Details

Insider Trades

Latest Guru Trades with STJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:ZBH, NAS:ISRG, NYSE:EW, NYSE:BSX, OTCPK:SNNUF, NYSE:VAR, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, OTCPK:CHEOY, NAS:ABMD, NYSE:SYK, OTCPK:EKTAY, NAS:NUVA, NAS:IART, NAS:MASI, NAS:LIVN, NYSE:NVRO, NAS:WMGI, NYSE:PEN » details
Traded in other countries:JUD.Germany,
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.

St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro

Ratios

vs
industry
vs
history
P/E(ttm) 35.32
STJ's P/E(ttm) is ranked lower than
63% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. STJ: 35.32 )
Ranked among companies with meaningful P/E(ttm) only.
STJ' s P/E(ttm) Range Over the Past 10 Years
Min: 12.69  Med: 21.63 Max: 51.47
Current: 35.32
12.69
51.47
Forward P/E 18.32
STJ's Forward P/E is ranked higher than
67% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. STJ: 18.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 35.32
STJ's PE(NRI) is ranked lower than
63% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. STJ: 35.32 )
Ranked among companies with meaningful PE(NRI) only.
STJ' s PE(NRI) Range Over the Past 10 Years
Min: 12.69  Med: 21.63 Max: 51.47
Current: 35.32
12.69
51.47
Price/Owner Earnings (ttm) 34.29
STJ's Price/Owner Earnings (ttm) is ranked lower than
56% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 30.39 vs. STJ: 34.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
STJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.98  Med: 22.24 Max: 136.33
Current: 34.29
10.98
136.33
P/B 5.13
STJ's P/B is ranked lower than
69% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. STJ: 5.13 )
Ranked among companies with meaningful P/B only.
STJ' s P/B Range Over the Past 10 Years
Min: 2.13  Med: 4.12 Max: 6.83
Current: 5.13
2.13
6.83
P/S 3.88
STJ's P/S is ranked lower than
60% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. STJ: 3.88 )
Ranked among companies with meaningful P/S only.
STJ' s P/S Range Over the Past 10 Years
Min: 1.85  Med: 3.19 Max: 6.94
Current: 3.88
1.85
6.94
PFCF 27.60
STJ's PFCF is ranked lower than
51% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. STJ: 27.60 )
Ranked among companies with meaningful PFCF only.
STJ' s PFCF Range Over the Past 10 Years
Min: 9.96  Med: 21.15 Max: 41.5
Current: 27.6
9.96
41.5
POCF 21.24
STJ's POCF is ranked lower than
60% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. STJ: 21.24 )
Ranked among companies with meaningful POCF only.
STJ' s POCF Range Over the Past 10 Years
Min: 7.95  Med: 15.1 Max: 28.29
Current: 21.24
7.95
28.29
EV-to-EBIT 32.46
STJ's EV-to-EBIT is ranked lower than
66% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. STJ: 32.46 )
Ranked among companies with meaningful EV-to-EBIT only.
STJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.1  Med: 19.4 Max: 34.2
Current: 32.46
10.1
34.2
EV-to-EBITDA 21.98
STJ's EV-to-EBITDA is ranked lower than
66% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. STJ: 21.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
STJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.5  Med: 15.3 Max: 27.9
Current: 21.98
8.5
27.9
PEG 19.28
STJ's PEG is ranked lower than
91% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. STJ: 19.28 )
Ranked among companies with meaningful PEG only.
STJ' s PEG Range Over the Past 10 Years
Min: 0.72  Med: 1.49 Max: 21.13
Current: 19.28
0.72
21.13
Shiller P/E 31.73
STJ's Shiller P/E is ranked higher than
65% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 46.10 vs. STJ: 31.73 )
Ranked among companies with meaningful Shiller P/E only.
STJ' s Shiller P/E Range Over the Past 10 Years
Min: 17.41  Med: 30.4 Max: 57.55
Current: 31.73
17.41
57.55
Current Ratio 1.93
STJ's Current Ratio is ranked lower than
65% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. STJ: 1.93 )
Ranked among companies with meaningful Current Ratio only.
STJ' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.51 Max: 4.53
Current: 1.93
1.14
4.53
Quick Ratio 1.31
STJ's Quick Ratio is ranked lower than
67% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. STJ: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
STJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.88 Max: 3.54
Current: 1.31
0.86
3.54
Days Inventory 165.81
STJ's Days Inventory is ranked lower than
63% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. STJ: 165.81 )
Ranked among companies with meaningful Days Inventory only.
STJ' s Days Inventory Range Over the Past 10 Years
Min: 146.43  Med: 162.13 Max: 177.06
Current: 165.81
146.43
177.06
Days Sales Outstanding 79.05
STJ's Days Sales Outstanding is ranked lower than
61% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. STJ: 79.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
STJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.88  Med: 91.7 Max: 98.89
Current: 79.05
78.88
98.89
Days Payable 42.79
STJ's Days Payable is ranked lower than
63% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. STJ: 42.79 )
Ranked among companies with meaningful Days Payable only.
STJ' s Days Payable Range Over the Past 10 Years
Min: 33.34  Med: 58.78 Max: 77.02
Current: 42.79
33.34
77.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.52
STJ's Dividend Yield is ranked lower than
56% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. STJ: 1.52 )
Ranked among companies with meaningful Dividend Yield only.
STJ' s Dividend Yield Range Over the Past 10 Years
Min: 0.39  Med: 1.67 Max: 2.81
Current: 1.52
0.39
2.81
Dividend Payout 0.54
STJ's Dividend Payout is ranked lower than
52% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. STJ: 0.54 )
Ranked among companies with meaningful Dividend Payout only.
STJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.28  Med: 0.33 Max: 0.94
Current: 0.54
0.28
0.94
Dividend Growth (3y) 8.00
STJ's Dividend Growth (3y) is ranked lower than
54% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. STJ: 8.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
STJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.7
Current: 8
0
8.7
Forward Dividend Yield 1.54
STJ's Forward Dividend Yield is ranked lower than
62% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. STJ: 1.54 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.53
STJ's Yield on cost (5-Year) is ranked lower than
57% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. STJ: 1.53 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
STJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.39  Med: 1.67 Max: 2.81
Current: 1.53
0.39
2.81
3-Year Average Share Buyback Ratio 1.50
STJ's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. STJ: 1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
STJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2  Med: 1.5 Max: 4.2
Current: 1.5
-2
4.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.78
STJ's Price/Projected FCF is ranked higher than
58% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. STJ: 1.78 )
Ranked among companies with meaningful Price/Projected FCF only.
STJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.62 Max: 5.41
Current: 1.78
0.91
5.41
Price/DCF (Earnings Based) 2.17
STJ's Price/DCF (Earnings Based) is ranked higher than
50% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. STJ: 2.17 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.22
STJ's Price/Median PS Value is ranked lower than
61% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. STJ: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
STJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.6  Med: 1.07 Max: 2.12
Current: 1.22
0.6
2.12
Earnings Yield (Greenblatt) (%) 3.07
STJ's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. STJ: 3.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
STJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 5.15 Max: 9.9
Current: 3.07
2.9
9.9
Forward Rate of Return (Yacktman) (%) 7.03
STJ's Forward Rate of Return (Yacktman) (%) is ranked lower than
55% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. STJ: 7.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
STJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 5.3  Med: 18.7 Max: 24.3
Current: 7.03
5.3
24.3

More Statistics

Revenue (TTM) (Mil) $5,956
EPS (TTM) $ 2.28
Beta1.02
Short Percentage of Float2.91%
52-Week Range $48.83 - 84.00
Shares Outstanding (Mil)285.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 6,041 6,297 6,727
EPS ($) 4.04 4.37 4.82
EPS w/o NRI ($) 4.04 4.37 4.82
EPS Growth Rate
(3Y to 5Y Estimate)
1.51%
Dividends Per Share ($) 1.08 1.12 1.42
» More Articles for NYSE:STJ

Headlines

Articles On GuruFocus.com
Abbott Laboratories Announces Quarterly Dividend Dec 09 2016 
Abbott: $15 Billion Available From Notes Nov 25 2016 
Abbott Laboratories CEO Buys Stock in Company Nov 15 2016 
Richard Perry Exits AIG, Time Warner Nov 14 2016 
First Eagle Investment Management's Top 5 Stock Buys of 3rd Quarter Nov 07 2016 
Mairs & Power Growth Fund 3rd Quarter Results Oct 31 2016 
Abbott, St. Jude Medical: vascular closure products sale's agreement Oct 20 2016 
Abbott Develops AML Tests With Celgene and Agios Oct 13 2016 
Abbott Tumbled on St. Jude Medical's News Oct 12 2016 
Numerous Companies Reach 52-Week Highs Aug 23 2016 

More From Other Websites
St. Jude Medical Announces Fourth Quarter Dividend Dec 09 2016
Should You Invest in St. Jude Medical, Inc. (STJ)? Dec 08 2016
8:01 am St. Jude Medical receives CE mark approval for full body MR conditional labeling for the... Dec 08 2016
St. Jude Medical Receives CE Mark Approval for Full Body MR Conditional Labeling for the Proclaim... Dec 08 2016
St. Jude Medical Receives CE Mark Approval for Full Body MR Conditional Labeling for the Proclaim... Dec 08 2016
St. Jude Medical, Inc. – Value Analysis (NYSE:STJ) : December 7, 2016 Dec 07 2016
St. Jude Medical, Inc. breached its 50 day moving average in a Bullish Manner : STJ-US : December 6,... Dec 06 2016
Is Dollar Tree, Inc. (DLTR) a Good Stock To Buy? Nov 26 2016
Abbott: $15 Billion Available From Notes Nov 25 2016
EU regulator conditionally approves Abbott's purchase of St Jude Nov 23 2016
EU regulator conditionally approves Abbott's purchase of St Jude Nov 23 2016
St. Jude Medical, Inc. breached its 50 day moving average in a Bearish Manner : STJ-US : November... Nov 23 2016
St. Jude Medical's MOMENTUM 3 IDE Study Results Encourage Nov 17 2016
[$$] Abbott, St. Jude Medical to Sell $1.1 Billion in Assets Nov 17 2016
St. Jude Medical HeartMate 3 LVAS Demonstrated Improved Clinical Outcomes for Patients Suffering... Nov 16 2016
European Union Regulators Said to Approve Abbott's St. Jude Acquisition Nov 16 2016
Exclusive: EU regulators seen clearing $25 billion Abbott, St Jude deal: source Nov 15 2016
Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal: source Nov 15 2016
ST JUDE MEDICAL INC Financials Nov 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)